Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Alendronate in OVCF after PVP
NCT05662358Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Lumbar bone mineral density at 12 months, Total hip bone mineral density at 12 months and 4 more. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05662358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662358.